Stefan Aretz

Stefan Aretz

Auto-generated profile, based on publicly available information

Stefan Aretz

University Hospital Bonn Institute of Human Genetics Venusberg-Campus 1 Bonn Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
RARonja Adam
Ronja Adam
ISIsabel Spier
Isabel Spier
BZBixiao Zhao
Bixiao Zhao
MKMichael Kloth
Michael Kloth
JMJonathan Marquez
Jonathan Marquez
SAStefan Aretz
Stefan Aretz

27 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AWAnja Wagner
Anja Wagner
SAStefan Aretz
Stefan Aretz
AAAnnika Auranen
Annika Auranen
Marco BrunoMarco Bruno
Marco Bruno
Giulia Martina CavestroGiulia Martina Cavestro
Giulia Martina Cavestro
GMGabriela Möslein
Gabriela Möslein
The scientific data to guide the management of Peutz–Jeghers syndrome (PJS) are sparse. The available evidence has been reviewed and discussed by diverse medical specialists in the field of PJS to update the previous guideline from 2010 and formulate a revised practical guideline for colleagues managing PJS patients. Methods: Literature searches were performed using MEDLINE, Embase, and Cochrane. Evidence levels and recommendation strengths were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). A Delphi process was followed, with consensus being reached when ≥80% of the voting guideline committee members agreed. Recommendations and statements: The only recent guidelines available were for gastrointestinal and pancreatic management. These were reviewed and endorsed after confirming that no more recent relevant papers had been published. Literature searches were performed for additional questions and yielded a variable number of relevant papers depending on the subject addressed. Additional recommendations and statements were formulated. Conclusions: A decade on, the evidence base for recommendations remains poor, and collaborative studies are required to provide better data about this rare condition. Within these restrictions, multisystem, clinical management recommendations for PJS have been formulated.

1 April 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CEChristoph Engel
Christoph Engel
AAAysel Ahadova
Aysel Ahadova
TSToni Seppälä
Toni Seppälä
SAStefan Aretz
Stefan Aretz
MBMarloes Bigirwamungu-Bargeman
Marloes Bigirwamungu-Bargeman
HVHans F. Vasen
Hans F. Vasen

15 September 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SHSukanya Horpaopan
Sukanya Horpaopan
ISIsabel Spier
Isabel Spier
AZAlexander M. Zink
Alexander M. Zink
JAJanine Altmüller
Janine Altmüller
SHStefanie Holzapfel
Stefanie Holzapfel
SAStefan Aretz
Stefan Aretz
To uncover novel causative genes in patients with unexplained adenomatous polyposis, a model disease for colorectal cancer, we performed a genome‐wide analysis of germline copy number variants (CNV) in a large, well characterized APC and MUTYH mutation negative patient cohort followed by a targeted next generation sequencing (NGS) approach. Genomic DNA from 221 unrelated German patients was genotyped on high‐resolution SNP arrays. Putative CNVs were filtered according to stringent criteria, compared with those of 531 population‐based German controls, and validated by qPCR. Candidate genes were prioritized using in silico , expression, and segregation analyses, data mining and enrichment analyses of genes and pathways. In 27% of the 221 unrelated patients, a total of 77 protein coding genes displayed rare, nonrecurrent, germline CNVs. The set included 26 candidates with molecular and cellular functions related to tumorigenesis. Targeted high‐throughput sequencing found truncating point mutations in 12% (10/77) of the prioritized genes. No clear evidence was found for autosomal recessive subtypes. Six patients had potentially causative mutations in more than one of the 26 genes. Combined with data from recent studies of early‐onset colorectal and breast cancer, recurrent potential loss‐of‐function alterations were detected in CNTN6, FOCAD (KIAA1797 ), HSPH1 , KIF26B, MCM3AP, YBEY and in three genes from the ARHGAP family. In the canonical Wnt pathway oncogene CTNNB1 (β‐catenin), two potential gain‐of‐function mutations were found. In conclusion, the present study identified a group of rarely affected genes which are likely to predispose to colorectal adenoma formation and confirmed previously published candidates for tumor predisposition as etiologically relevant.

28 February 2019 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
TSToni Seppälä
Toni Seppälä
AAAysel Ahadova
Aysel Ahadova
MDMev Dominguez-Valentin
Mev Dominguez-Valentin
FMFinlay Macrae
Finlay Macrae
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
PMPål Moller
Pål Moller
Recent epidemiological evidence shows that colorectal cancer (CRC) continues to occur in carriers of pathogenic mismatch repair (path_MMR) variants despite frequent colonoscopy surveillance in expert centres. This observation conflicts with the paradigm that removal of all visible polyps should prevent the vast majority of CRC in path_MMR carriers, provided the screening interval is sufficiently short and colonoscopic practice is optimal. To inform the debate, we examined, in the Prospective Lynch Syndrome Database (PLSD), whether the time since last colonoscopy was associated with the pathological stage at which CRC was diagnosed during prospective surveillance. Path_MMR carriers were recruited for prospective surveillance by colonoscopy. Only variants scored by the InSiGHT Variant Interpretation Committee as class 4 and 5 (clinically actionable) were included. CRCs detected at the first planned colonoscopy, or within one year of this, were excluded as prevalent cancers. Stage at diagnosis and interval between last prospective surveillance colonoscopy and diagnosis were available for 209 patients with 218 CRCs, including 162 path_MLH1, 45 path_MSH2, 10 path_MSH6 and 1 path_PMS2 carriers. The numbers of cancers detected within < 1.5, 1.5–2.5, 2.5–3.5 and at > 3.5 years since last colonoscopy were 36, 93, 56 and 33, respectively. Among these, 16.7, 19.4, 9.9 and 15.1% were stage III–IV, respectively (p = 0.34). The cancers detected more than 2.5 years after the last colonoscopy were not more advanced than those diagnosed earlier (p = 0.14). The CRC stage and interval since last colonoscopy were not correlated, which is in conflict with the accelerated adenoma-carcinoma paradigm. We have previously reported that more frequent colonoscopy is not associated with lower incidence of CRC in path_MMR carriers as was expected. In contrast, point estimates showed a higher incidence with shorter intervals between examinations, a situation that may parallel to over-diagnosis in breast cancer screening. Our findings raise the possibility that some CRCs in path_MMR carriers may spontaneously disappear: the host immune response may not only remove CRC precursor lesions in path_MMR carriers, but may remove infiltrating cancers as well. If confirmed, our suggested interpretation will have a bearing on surveillance policy for path_MMR carriers.

1 October 2021 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
SLSilvana Lobo
Silvana Lobo
PBPatrick Benusiglio
Patrick Benusiglio
FCFlorence Coulet
Florence Coulet
LBLise Boussemart
Lise Boussemart
LGLisa Golmard
Lisa Golmard
COCarla Oliveira
Carla Oliveira